The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).
Austin G. Duffy
No relevant relationships to disclose
Susanna Varkey Ulahannan
No relevant relationships to disclose
Suzanne Fioravanti
No relevant relationships to disclose
Melissa Walker
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
Kathryn Compton
No relevant relationships to disclose
Aradhana Venkatesan
No relevant relationships to disclose
Nadine Abi-Jaoudeh
No relevant relationships to disclose
Bradford J. Wood
No relevant relationships to disclose
Tim F. Greten
No relevant relationships to disclose